Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR-HIFU for Uterine Fibroids in Northwestern Ontario
NCT02736435Phase 3Withdrawn
- Sponsor
- Thunder Bay Regional Health Research Institute
- Start
- Jan 2018
- Primary completion
- Jan 2018
- Countries
- 1
01
Overview
Phase 3, open-label trial (2 arms), sponsored by Thunder Bay Regional Health Research Institute. Primary endpoint: Change in uterine fibroid symptom severity scale at 12 months. Planned start Jan 2018; status: withdrawn.
Beyond the preview
Go deeper on NCT02736435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736435.